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patients with a claim for SA per 100 patient-years of treatment
exposure. RESULTS: A total of 140 MRA patients were identi-
ﬁed and matched to 420 nBZRA and 420 BZD patients by age
(mean 46 years), sex (64% female), race (57% white), depression
(50%), and anxiety (14%). The mean Charlson co-morbidity
score was higher for MRA patients (1.4) than nBZRA or BZD
patients (0.6 and 0.7, respectively, P < 0.01). The SA rate per 100
patient-years of exposure was 1.84 and 2.51 for nBZRA and
BZD patients, respectively. There was no evidence of substance
abuse among the MRA cohort. CONCLUSION: These initial
data suggest that MRA patients were less likely to use medical
services for substance abuse than nBZRA or BZD patients.
However, given the small number of patients in this study, no
deﬁnitive conclusions can be drawn. Additional data will be
needed to conﬁrm these ﬁndings.
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Smith TW1, Kowal-Podmore S1, Runken MC2
1IMS Consulting, Falls Church,VA, USA, 2GlaxoSmithKline, Research
Triangle Park, NC, USA
OBJECTIVE: To estimate the potential impact of a ﬁxed-dose
combination of sumatriptan 85mg and naproxen sodium 500mg
(suma/nap) on triptan consumption in a United States managed
care population of moderate-to-severe adult migraineurs.
METHODS: A payer-perspective pharmacy budget impact
model was developed using Microsoft Excel®. Dose-speciﬁc
efﬁcacy was drawn from published meta-analyses for suma-
triptan, eletriptan, rizatriptan, zolmitriptan, almotriptan, and
naratriptan, and derived from published trials for suma/nap.
Initial response rates at two hours, recurrence rates, and 24-hour
sustained pain free rates were used to model mean triptans con-
sumed per migraine episode. Nationally representative data for
market share and quantity dispensed from commercial sources as
well as prevalence data from the literature were combined with
modeled triptan consumption to estimate the number of total
annual prescriptions (TRx) ﬁlled. Probabilistic and scenario-
based sensitivity analyses were used to assess model uncertainty.
RESULTS: In a hypothetical plan of 1,000,000 covered lives, an
estimated 14,540 moderate-to-severe adult migraineurs treated
with currently available triptans ﬁlled 102,206 TRx. Of the 12
triptan doses evaluated, suma/nap had the lowest mean triptan
consumption per migraine episode (1.08; CI 1.06–1.09), fol-
lowed by naratriptan 2.5mg (1.10; CI 1.06–1.14), eletriptan
20mg (1.14; CI 1.09–1.19), and sumatriptan 25mg (1.15; CI
1.13–1.18). After converting 8.6% of TRx share (58.3% from
sumatriptan and 41.7% from other triptans according to market
share) to suma/nap, migraineurs ﬁlled only 100,356 TRx, a net
reduction of 1,850 prescriptions [CI 1,714–1,965]. In a second
scenario converting 8.6% of TRx share (100% from suma-
triptan), migraineurs ﬁlled 101,253 TRx, a net reduction of
953 prescriptions [CI 811–1,076]. CONCLUSION: Treating
a portion of moderate-to-severe migraineurs with suma/nap
reduced triptan consumption in a hypothetical nationally repre-
sentative managed care plan. Further research is required to
quantify the potential economic impact of this reduction once
suma/nap pricing is established.
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OBJECTIVE: To estimate the budget impact of switching from
Rivastigmine capsules to Rivastigmine Transdermal Adhesives in
Brazilian Public Health System. METHODS: A simulation model
from Public Health System perspective, with a time horizon of
three years was developed. In order to explore the minimum and
maximum possible budget impact, two scenarios were per-
formed. In the scenario A the patients are kept in the current
treatment dosage proﬁle using transdermal adhesive. In scenario
B the patients are successfully switched to higher doses using
transdermal adhesives as label and clinical studies recommenda-
tions. The capsules formulations analyzed were: 1.5 mg; 3 mg;
4.5 mg e 6 mg. The transdermal formulations evaluated were
5 cm2 and 10 cm2. The indication of target dose of 10 cm2
rivastigmine transdermal adhesives provides efﬁcacy similar to
the highest doses of capsules was based on clinical and pharma-
cological trials. Data from medication unit’s dispensation were
collected from public health database, ranging from October
2004 to September 2007. Cost information was collected from
ofﬁcial reimbursement list. The rate of switching from capsules to
transdermal adhesives was based on randomized controlled trial
related to caregiver preference. Results were converted in US
Dollars (R$ 1,8/USD 1.00). A one-way sensitivity analysis was
performed. RESULTS: In scenario A it was estimated that the
government could obtain a reduction of USD$2.7 million, or
6.02% of expenses. A reduction of 37% of pharmacy dispensa-
tion activities was associated with lowest health service resource
utilization. On the other hand in scenario B government expenses
are 6.36% higher (USD$3.2 million) but with reduction of 31%
of pharmacy dispensation activities. All scenarios are sensible
to transdermal adhesives costs. CONCLUSION: Rivastigmine
transdermal adhesives would be advantageous to Brazilian Public
Health System providing budget savings with lower resource
utilization. Although higher dosage of medication increases
expenses, pharmacy dispensation activities would be lower.
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OBJECTIVE: To compare medical costs among switching, dis-
continuing and persisting patients on multiple sclerosis (MS)
treatment. METHODS: Using the PharMetrics medical claims
database, adults diagnosed with MS who initiated treatment with
interferon beta (A-Avonex, B-Betaseron, R-Rebif) or glatiramer
acetate (C-Copaxone) in 1996–2005 were identiﬁed. Within each
drug initiator group, patients who persisted with the index treat-
ment, switched drugs, and discontinued MS medications, during
the ﬁrst 18 months after drug start were identiﬁed. Total medical
costs for the 18 months following treatment switch or discon-
tinuation, and for a randomly selected 18-month period among
those who persisted, were compared using multivariate linear
regression models. RESULTS: Among 6073 patients who initi-
ated treatment, the mean age was 43 years, 78% were female,
and 16% had treatment with a different MS drug prior to index
drug start. At 18 months after start of the index drug, 3365
(55%) of patients persisted; 685 (11%) switched, and 2023
(33%) of patients discontinued treatment for at least 90 days.
Mean medical costs over 18 months were $10,718, $8,786, and
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